ICUI

Business Context and Reporting Period

Company: ICU Medical, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2007
Business Overview: ICU Medical develops, manufactures, and markets disposable medical devices, primarily for intravenous (I.V.) therapy and critical care applications. The company operates principally in one segment and relies heavily on a long-term Manufacturing, Commercialization and Development Agreement (MCDA) with Hospira, Inc., which accounted for approximately 74% of total revenue in the first half of 2007.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 4.9% in Q2 2007 compared to Q2 2006. On a comparable basis (excluding discontinued products), revenue increased 3%. The decline was driven by lower sales of critical care products to Hospira due to lower unit volumes and pricing under the MCDA.
• Profitability Impact: Net income dropped significantly in Q2 2007 ($2.5M vs $6.3M in Q2 2006). This was primarily due to a $4.8 million legal fee charge related to patent litigation with Alaris Medical Systems, recorded in "Other Income (Expense)."
• Gross Margin Compression: Gross margin decreased from 45% in Q2 2006 to 42% in Q2 2007. Management attributed this to production inefficiencies at facilities in Salt Lake City and Mexico, estimated at $1.2 million for the quarter.
• Customer Concentration: Sales to Hospira remained dominant, representing 73% of Q2 2007 revenue. Sales to independent domestic distributors and international customers grew 16% and 31% respectively in Q2 2007.
• Capital Expenditures: Investing cash outflows increased significantly due to $14.2 million in purchases of property and equipment, primarily for the expansion of the Mexico facility.

Guidance, Outlook, and Risks

• Outlook: Management expects gross margins to approach 45% by December 2007 as production inefficiencies are resolved. SG&A is expected to approximate 24% of revenue for the full year, and R&D is expected to be 4-5% of revenue.
• Legal Contingencies:
  • Alaris Litigation: The company was ordered to pay $4.8 million in fees and costs following the dismissal of its patent infringement claims against Alaris. The company intends to appeal and has not paid the judgment pending the outcome.
  • Medegen Litigation: Medegen alleges patent infringement regarding the CLC 2000 and Tego products. The company believes it is not infringing and is awaiting a court decision on a summary judgment motion.
  • Settlement: The company received an $8.0 million settlement in January 2007 from its former attorneys (Fulwider), which boosted income in the first half of 2007.
• Risk Factors:
  • Customer Dependence: Significant reliance on Hospira (approx. 74% of revenue). An adverse change in this relationship or Hospira's market position could materially harm the company.
  • Market Decline: The U.S. market for critical care products is declining, which may continue to reduce sales under the MCDA.
  • Intellectual Property: Risks associated with enforcing patents against competitors and defending against infringement claims.

Investor Verification Checklist

• Legal Exposure: Verify the status of the appeal regarding the $4.8 million Alaris judgment and the potential for additional costs or liability.
• Production Efficiency: Monitor Q3 and Q4 results to confirm if gross margins recover to the projected 45% as production inefficiencies in Mexico and Salt Lake City are resolved.
• Hospira Relationship: Assess the stability of the MCDA and Hospira's sales performance, given the 74% revenue concentration and the declining critical care market.
• Discontinued Products: Review future revenue projections excluding the impact of discontinued products (Punctur-Guard and specific MCDA items) to gauge organic growth.
• Cash Position: Confirm the sustainability of the $110 million cash and liquid investment position against the projected $23 million capital expenditure plan for 2007.